Clinical Trial Update: Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study) [Phase 2]

View source ↗

Summary

Phase 2 SMILE trial evaluating Onapristone in combination with Fulvestrant for ER-positive, HER2-negative metastatic breast cancer after endocrine therapy and C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Fulvestrant (fulvestrant)
• Onapristone (onapristone)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2024-05-03